Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine for Imminent Relapse in AML/MDS Post-HSCT (RELAZA)
NCT00422890Phase 3Completed
- Sponsor
- Technische Universität Dresden
- Start
- Jan 2007
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of azacitidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Technische Universität Dresden. Primary endpoint: Efficacy (Response Rate defined by CD34 chimerism improvement) at 4 months. Started Jan 2007; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00422890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422890.